Microglia tend to get off-kilter in Alzheimer’s and other neurodegenerative diseases. Now, researchers in Tony Wyss-Coray’s lab at Stanford University believe they have discovered a means of restoring their homeostasis. On April 3 in Nature online, they reported that blocking CD22, a cell surface receptor associated with B cells, reprograms microglia to look more like those in young, healthy mice, the scientists contend. The blockade unleashed phagocytosis of aggregated Aβ, α-synuclein, and other cellular debris in old mice, and improved their memories.
- CD22 popped up in screening for suppressors of microglial phagocytosis.
- The receptor is upregulated in aging mice and in Alzheimer’s.
- Blocking CD22 improves phagocytosis and memory in old mice.
“I think the most exciting aspect is that microglia almost act like B cells,” said Wyss-Coray. Decades of research have outlined how signaling through CD22, as in cluster of differentiation, suppresses B cells after they recognize an antigen. This is a control mechanism to prevent overactivation of an immune response. In aging microglia, the Stanford scientists now propose, CD22 may similarly be suppressing normal functions, such as mopping up cellular debris and toxic proteins.
First author John Pluvinage and colleagues identified CD22 in a CRISPR-based search for transcripts that suppress or enhance phagocytosis. The researchers used 30,000 guide RNAS to target about 3,000 genes, including 950 transmembrane proteins and about 2,000 known drug targets. They first screened BV2 microglia-like cells by CRISPR, then compared that data to RNA-Seq transcriptional profiles of microglia from young and aged mice. They were searching for phagocytosis suppressors or enhancers that change with age.
Only CD22 fit the bill. Knocking it out with CRISPR boosted phagocytosis in BV2 cells, while microglia from older mice had fivefold more CD22 than did cells from young mice, as reported previously (Hickman et al., 2013; Grabert et al., 2016). CD22 also appears to be upregulated in AD (Friedman et al., 2018).
CD22 belongs to the family of sialic acid-binding immunoglobulin-like lectins, or Siglecs, which also includes CD33. Variants in CD33 suppress Aβ phagocytosis and increase risk for Alzheimer’s disease (Griciuc et al., 2013; Aug 2013 news).
To test if CD22 acts similarly, Pluvinage injected Aβ oligomers bilaterally into the brains of 14- to 16-month-old mice, adding an antibody against CD22 to one hemisphere and a control IgG to the other. The anti-CD22 treatment spurred clearance of Aβ within two days (see image below). In separate experiments, anti-CD22 similarly cleared injected myelin and α-synuclein fibrils. Taking a different approach, the authors found they could inhibit phagocytosis using lipid-bound synthetic glycopolymers that mimic the sialic acid ligands that activate CD22 (see image below). These failed to block phagocytosis in CD22 knockout cells.
How would CD22 blockade promote microglial phagocytosis? CD22 recruits tyrosine phosphatase SHP-1/PTPN6 to inhibit immune receptor signaling and Wyss-Coray believes CD22 antibodies antagonize inhibitory signaling in phagocytic receptors, thereby restoring phagocytosis. “What is really surprising is that the whole transcriptional profile of these cells changes, not just phagocytosis,” said Wyss-Coray. After one month of continuous CD22 blockade, microglia from 18-month-old wild-type mice assumed a transcriptional profile resembling that of microglia from 3-month-old mice. They had turned down expression of genes upregulated during aging, and increased expression of genes suppressed by age. In each case, genes associated with microglial homeostasis, such as P2ry13, Sall1, Il10ra, and Mef2a, were more active, and disease-associated genes, including Tspo, Lgals3, Tnfsf13b and Ccl3, shut down (Jun 2017 news). In the old mice, this shift appeared to improve synaptic plasticity, as indicated by more c-fos in the dentate gyrus. They also spent more time exploring a novel object in a Y maze, and froze longer in a contextual fear experiment, both indications of better memory.
Wyss-Coray is exploring how to exploit this receptor to treat AD and potentially other neurodegenerative diseases of aging.
Alector, a biotech company in South San Francisco, has begun a Phase I clinical trial of an anti-CD33/Siglec3 antibody in healthy controls and AD patients.—Tom Fagan.
- Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, El Khoury J. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013 Dec;16(12):1896-905. Epub 2013 Oct 27 PubMed.
- Grabert K, Michoel T, Karavolos MH, Clohisey S, Baillie JK, Stevens MP, Freeman TC, Summers KM, McColl BW. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat Neurosci. 2016 Mar;19(3):504-16. Epub 2016 Jan 18 PubMed.
- Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PC, Ngu H, Modrusan Z, Larson JL, Kaminker JS, van der Brug MP, Hansen DV. Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer's Disease Not Evident in Mouse Models. Cell Rep. 2018 Jan 16;22(3):832-847. PubMed.
- Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013 May 22;78(4):631-43. PubMed.
No Available Further Reading
- Pluvinage JV, Haney MS, Smith BA, Sun J, Iram T, Bonanno L, Li L, Lee DP, Morgens DW, Yang AC, Shuken SR, Gate D, Scott M, Khatri P, Luo J, Bertozzi CR, Bassik MC, Wyss-Coray T. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature. 2019 Apr;568(7751):187-192. Epub 2019 Apr 3 PubMed.